BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17724468)

  • 1. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
    Mahanivong C; Chen HM; Yee SW; Pan ZK; Dong Z; Huang S
    Oncogene; 2008 Feb; 27(9):1273-80. PubMed ID: 17724468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
    Li H; Ye X; Mahanivong C; Bian D; Chun J; Huang S
    J Biol Chem; 2005 Mar; 280(11):10564-71. PubMed ID: 15653692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
    Jeong KJ; Park SY; Cho KH; Sohn JS; Lee J; Kim YK; Kang J; Park CG; Han JW; Lee HY
    Oncogene; 2012 Sep; 31(39):4279-89. PubMed ID: 22249252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells.
    Cheng CY; Hsieh HL; Sun CC; Lin CC; Luo SF; Yang CM
    J Cell Physiol; 2009 Apr; 219(1):183-93. PubMed ID: 19097143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
    Estrella VC; Eder AM; Liu S; Pustilnik TB; Tabassam FH; Claret FX; Gallick GE; Mills GB; Wiener JR
    Int J Oncol; 2007 Aug; 31(2):441-9. PubMed ID: 17611702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB.
    Sliva D; English D; Lyons D; Lloyd FP
    Biochem Biophys Res Commun; 2002 Jan; 290(1):552-7. PubMed ID: 11779207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells.
    McAllister-Lucas LM; Ruland J; Siu K; Jin X; Gu S; Kim DS; Kuffa P; Kohrt D; Mak TW; Nuñez G; Lucas PC
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):139-44. PubMed ID: 17101977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
    Bian D; Su S; Mahanivong C; Cheng RK; Han Q; Pan ZK; Sun P; Huang S
    Cancer Res; 2004 Jun; 64(12):4209-17. PubMed ID: 15205333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
    Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
    Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
    Chan CF; Yau TO; Jin DY; Wong CM; Fan ST; Ng IO
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4140-9. PubMed ID: 15217951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
    So J; Wang FQ; Navari J; Schreher J; Fishman DA
    Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
    Pustilnik TB; Estrella V; Wiener JR; Mao M; Eder A; Watt MA; Bast RC; Mills GB
    Clin Cancer Res; 1999 Nov; 5(11):3704-10. PubMed ID: 10589790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine production.
    Klemm S; Zimmermann S; Peschel C; Mak TW; Ruland J
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):134-8. PubMed ID: 17095601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells.
    Kim MH; Park JS; Chang HJ; Baek MK; Kim HR; Shin BA; Ahn BW; Jung YD
    J Cell Biochem; 2008 Jun; 104(3):1102-12. PubMed ID: 18247343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity.
    Hwang YS; Hodge JC; Sivapurapu N; Lindholm PF
    Mol Carcinog; 2006 Jul; 45(7):518-29. PubMed ID: 16402387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The LUBAC participates in lysophosphatidic acid-induced NF-κB activation.
    Douanne T; Chapelier S; Rottapel R; Gavard J; Bidère N
    Cell Immunol; 2020 Jul; 353():104133. PubMed ID: 32450431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
    Moreau M; Mourah S; Dosquet C
    Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-arrestin 2 is required for lysophosphatidic acid-induced NF-kappaB activation.
    Sun J; Lin X
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17085-90. PubMed ID: 18952848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells.
    Wang GL; Wen ZQ; Xu WP; Wang ZY; Du XL; Wang F
    Croat Med J; 2008 Apr; 49(2):175-81. PubMed ID: 18461672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor.
    Chou CH; Wei LH; Kuo ML; Huang YJ; Lai KP; Chen CA; Hsieh CY
    Carcinogenesis; 2005 Jan; 26(1):45-52. PubMed ID: 15471896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.